Effect of treatment with epoetin beta on thromboembolic events in anemic patients with cancer: A metaanalysis

Supportive Cancer Therapy

Volumn 4, Issue 1, 2006, Pages 49-55

  Coiffier, Bertrand ^a   Boogaerts, Marc ^b   Aapro, Matti ^c   Hayward, Colin ^d   Burger, Hans Ulrich ^d  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Erythropoietin; Hemoglobin; Safety

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE REACTION; INTESTINE NECROSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 33751167198     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.031     Document Type: Article

References (25)

1. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 15:174-182.
2. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9:255-260.
3. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin Alfa Study Group. J Clin Oncol 2001; 19:2865-2874.
4. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. Epoetin Beta Hematology Study Group. J Clin Oncol 2002; 20:2486-2494.
5. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:1211-1220.
6. Boogaerts M, Coiffier B, Kainz C. Impact of epoetin beta on quality of life in patients with malignant disease. Epoetin Beta QOL Working Group. Br J Cancer 2003; 88:988-995.
7. Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122:386-393.
8. Pujade-Lauraine E, Richard AJ, Sapède C. Erythropoietic agents in routine clinical practice: a retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in anaemic patients with cancer. Ann Oncol 2004; 15(suppl 3):iii220 (Abstract #835P).
9. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. BEST Investigators and Study Group. Lancet Oncol 2003; 4:459-460.
10. Rosenzweig MQ, Bender CM, Lucke JP, et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27:185-190.
11. Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease. Cochrane Library 2004; 3:CD003407.
12. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-714.
13. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-815.
14. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107(suppl 1):117-121.
15. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349:109-111.
16. Van Gerpen R, Mast ME. Thromboembolic disorders in cancer. Clin J Oncol Nurs 2004; 8:289-299.
17. Aapro M, Dunst J, Morère J-F, et al. Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 2004; 15(suppl 3):iii222 (Abstract #841P).
18. Österborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87:2675-2682.
19. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-4453.
20. Rau B, Schlag PM, Willeke F, et al. Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Eur J Cancer 1998; 34:992-998.
21. Kettelhack C, Hones C, Messinger D, et al. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 1998; 85:63-67.
22. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40:2201-2216.
23. NeoRecormon® SmPC. Available at: http://www.rocheuk.com/productdb/ documents/rx/spc/neorecormon_pfs_spc.pdf. Accessed August 1, 2006.
24. Eprex® SmPC. Available at: http://emc.medicines.org.Uk/emc/assets/c/ html/displaydoc.asp?documentid=889. Accessed August 1, 2006.
25. Aranesp® SmPC. Available at: http://www.wales.nhs.uk/sites/documents/ 371/enc4%20appendix3%20aranesp%20smpc.pdf. Accessed August 1, 2006.